vendredi 15 mars 2019

Onco Actu du 15 mars 2019


1. BIOLOGIE



Early-life exposure to microbiota restricts colon cancer later in life [ecancer News]











Oral bacteria in pancreas linked to more aggressive tumours [Karolinska Institutet]











2.6 ETIOLOGIE - ENVIRONNEMENT



Breast cancer risk tied to DDT varies by exposure timing [Reuters]











3.1 PRÉVENTION - TABAC



Tobacco, E-Cigarette Lobbyists Circle as F.D.A. Chief Exits [NY Times]










3.1.1 PRÉVENTION - TABAC - E-CIGS



FDA rolls out vaping policy to make it harder for minors to buy flavored products [Washington Post]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Early Detection Is Possible for Pancreatic Cancer [NY Times]











Cancer screening: A modest proposal for prevention [Cleveland Clinic Journal of Medicine]











4.9 DÉP., DIAG. & PRONO. - SEIN



BRCA Screening Guidelines Too Reliant on Family History, Stakeholders Tell USPSTF [Genome Web]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



A new approach to drugging a difficult cancer target [MIT]











Drug could alleviate side effects of chemo for breast cancer patients [Stanford Medicine]











5.12 IMMUNOTHÉRAPIES



UK gets early access to Roche’s breast cancer immunotherapy [Pharmaforum]











Cancer Neoantigens: Implications for Immune Response and Cancer Immunotherapy [ESMO]











5.12.6 IMMUNOTHÉRAPIES - AMM



European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) [Merck]











Merck notches fourth lung cancer approval in Europe for flagship Keytruda [EndPoints]










5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



CAR T cell immunotherapy for lymphoma rejected in Scotland [Cancer Research UK]











5.2 PHARMA



Merck limits orders for bladder cancer drug as demand outstrips supply [Fierce Pharma]










5.2.2 PHARMA - FUSIONS & ACQUISITIONS



BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge [Fierce Pharma]











Bristol-Myers dodges a bullet as PTAB turns down inter partes review pitch for Celgene’s cash cow [EndPoints]











U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug [Reuters]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Statement by FDA Commissioner Scott Gottlieb, M.D., on new strategies to modernize clinical trials to advance precision medicine, patient protections and more efficient product development [FDA]










6. LUTTE CONTRE LES CANCERS



It takes a village [Science]











Data sharing for pediatric cancers [Science]










6.1 OBSERVATION



One in four cancer patients wait two months for treatment, as NHS performance hits record low [The Telegraph]











NHS let me down, says health manager with cancer [BBC News]











6.12 ETHIQUE



Adopt a moratorium on heritable genome editing [Nature]











Germline gene-editing research needs rules [Nature]











6.6 PUBLICATIONS



Making Waves – Assessing the potential impacts of Plan S on the scholarly communications ecosystem [LSE Impact Blog]










Norway Joins List of Countries Canceling Elsevier Contracts [The Scientist]











6.7 DMP, BIG DATA & APPLIS



EMBL European Bioinformatics Institute Awarded £45M from UK Government [Genome Web]











£45 million boost for big data bioinformatics research to drive discovery [BBSRC]











6.9 CONTROVERSES



Johnson & Johnson chalks up another talc loss with $29M mesothelioma verdict [Fierce Pharma]











Johnson & Johnson Hit With $29 Million Verdict in Case Over Talc and Asbestos [NY Times]